HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

AIDS

Volumn 12, Issue 13, 1998, Pages 1611-1618

  Craig, Charles ^a   Race, Esther ^a   Sheldon, Jonathan ^a   Whittaker, Lynne ^a   Gilbert, Sue ^a   Moffatt, Alec ^a   Rose, Jane ^a   Dissanayeke, Shobana ^a   Chirn, Gung Wei ^b   Duncan, Ian B ^a   Cammack, Nick ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

HIV protease; HIV proteinase; Resistance; Saquinavir

Indexed keywords

AMPRENAVIR; GELATIN; INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG FORMULATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; CARBAMATES; CLINICAL TRIALS; DATABASES, FACTUAL; DNA, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LINKAGE (GENETICS); METHIONINE; NELFINAVIR; PHENOTYPE; POLYMERASE CHAIN REACTION; RITONAVIR; SAQUINAVIR; SULFONAMIDES; VALINE;

EID: 7344249601     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00007     Document Type: Article

References (37)

1. Peng C, Ho BK, Chang TW, Chang NT: Role of human immunodeficiency virus type 1-specific prolease in core protein maturation and viral infectivity. J Virol 1989, 63:2550-2556.
2. Kaplan AH, Zack JA, Knigge M, et al.: Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993, 67:4050-4055.
3. Kohl NE, Emini EA, Schleif WA, et al.: Active HIV protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
4. Bryant M, Getman D, Smith M, et al.: SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1995, 39:2229-2234.
5. Dorsey BD, Levin RB, McDaniel SL, et al.: L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994, 37:3443-3451.
6. Kageyama S, Weinstein JN, Shirasaka T, et al.: In vitro inhibition of HIV-1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 1992, 36:926-933.
7. Kempf DJ, Codacovi L, Wang XC, et al.: Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem 1993, 36:320-330.
8. Otto MJ, Reid CD, Garber S, et al.: In vitro anti-HIV activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother 1993, 37:2606-2611.
9. Pillay D, Bryant M, Getman D, Richman DD: HIV-1 protease inhibitors: their development, mechanism of action and clinical potential. Rev Med Virol 1995, 5:23-33.
10. Roberts NA, Martin JA, Kinchington D, et al.: Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248:358-361.
11. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS: Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991, 16:295-305.
12. Condra J, Holder D, Schlief W, et al.: Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor. J Virol 1996, 70:8270-8276.
13. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
14. Jacobsen H, Hanggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996, 173:1-9.
15. Jacobsen H, Yasargil K, Craig JC, Krohn A, Duncan IB, Mous J: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995, 206:527-534.
16. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of HIV-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
17. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.
18. Partaledis JA, Yamaguchi K, Tisdale M, et al.: In vitro selection and characterisation of HIV-1 isolates with reduced sensitivity to hydroxyethylamino sulphonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
19. Patick AD, Cao M, Ho Y, et al.: Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Antiviral Therapy: HIV Drug Resistance, 5th International Workshop. Whistler, July 1996 [abstract 29].
20. Patick AK, Mo H, Markowitz M, et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV protease. Antimicrob Agents Chemother 1996, 40:292-297.
21. Goudsmit J, Deronde A, Ho D, Perelson A: HIV fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996, 70:5662-5664.
22. Gulnik SV, Suvorov LI, Liu B, et al.: Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34:9282-9287.
23. Race E, Gilbert, S, Sheldon J, et al.: Genotypic changes selected in vivo during Phase III clinical trials with saquinavir in combination with reverse transcriptase inhibitors: frequencies and correlation with drug sensitivity and response to treatment. AIDS 1998, 12:1465-1474.
24. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996, 2:753-759.
25. Lech WJ, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of HIV-1: presence of protease inhibitor resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
26. Salgo M, Beattie D, Bragman K: Saquinavir (INVIRASE™, SQV) vs. Hivid (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). XI International Conference on AIDS. Vancouver, July 1996 [abstract 24].
27. AIDS Clinical Trials Group Virology Advisory Committee: Qualitative PBMC macroculture assay. In ACTG Virology Manual for HIV Laboratories. Washington DC: ACTG; 1994:MAC1-4.
28. AIDS Clinical Trials Group Virology Advisory Committee: HIV drug susceptibility assay. In ACTG Virology Manual for HIV Laboratories. Washington DC: ACTG; 1994:RES1-12.
29. 50: a critique. Biometrics 1950, 6:413-423.
30. Chou T-C: The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy. Edited by Chou I-C, Rideout J. New York: Academic Press; 1991:61-102.
31. Craig J, Sheldon J, Race E, Sitbon G: Phenotypic and genotypic resistance to HIV proteinase inhibitors (PIs): strategies that may lead to under-reporting. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 599].
32. Dulioust A, Paulous S, Guillemot L, Boue F, Galanaud P, Clavel F: Selection of saquinavir-resistance mutants by indinavir following a switch from saquinavir. Antiviral Therapy: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg (FL), 25-28 June 1997 [abstract 16].
33. Para MF, Collier A, Coombs R, et al.: ACTG 333: antiviral effects of switching from saquinavir hard capsule (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs. switching to indinavir (IDV) after prior saquinavir. 35th IDSA Annual Meeting. San Francisco, 13-16 September 1997 [abstract 21].
34. Para MF, Coombs R, Collier A, et al.: Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, 1-5 February 1998 [abstract 511].
35. Bodsworth N, Slade M, Ewan J, McNally L: RTV and IDV therapy at 28 weeks after 32 weeks SQV therapy-influence of HIV-1 protease mutations. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, 1-5 February 1998 [abstract 396].
36. Walmsley S, Clark J, Moses A, Salit I, Fletcher D: Can protease inhibitors be used in sequence in patients with advanced HIV infection? Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, 11-15 October 1997 [abstract 462].
37. Schinazi RF, Larder BA, Mellors JW: Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997, 5:129-137.